Abstracts tagged "Uric Acid, Urate"

Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
Abstract Number: 2018 • ACR Convergence 2024
Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study
Tillmann Uhlig¹, Lars F Karoliussen¹, Joseph Sexton², Sella A. Provan², Espen A. Haavardsholm³, Nicola Dalbeth⁴ and Hilde B Hammer¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: People with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy…
Abstract Number: 0275 • ACR Convergence 2024
Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation
Sadiq Umar¹ and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago
Background/Purpose: Gout, the leading cause of inflammatory arthritis, is becoming increasingly prevalent worldwide, affecting both developed and developing countries. This condition results from the deposition…
Abstract Number: 2019 • ACR Convergence 2024
Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies
Michael Pillinger¹, Alan Kivitz², Atul Singhal³, Anand Patel⁴, Rehan Azeem⁵, Aletta Falk⁶, Bhavisha Desai⁷, Hugues Santin-Janin⁸ and Herbert Baraf⁹, ¹New York University Grossman School of Medicine, New York,, NY, ²Altoona Center for Clinical Research, Duncansville, PA, ³Southwest Arthritis Research Group, Mesquite, TX, ⁴Conquest Research, Winter Park, FL, ⁵Sobi Inc., Waltham, MA, ⁶Sobi, Stockholm, Sweden, ⁷Sobi, Glastonbury, CT, ⁸Sobi, BETTENDORF (68560), France, ⁹Center for Rheumatology and Bone Research, Wheaton, MD
Background/Purpose: The DISSOLVE Phase 3 study program investigated the efficacy and safety of SEL-212, a novel, once-monthly, two-component infusion therapy consisting of pegadricase (SEL-037, a…
Abstract Number: 0279 • ACR Convergence 2024
Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals
Charles Leroy¹, Nghia Pham², François Brial³, Brenda Kischkel⁴, gwénaêlle Jayat⁵, Elena Ishow⁶, Christèle Combes⁷, Leo Joosten⁴, Augustin Latourte⁸, Pascal Richette⁹ and Hang-Korng Ea¹⁰, ¹Inserm 1132 / Université Paris Cité, levallois-perret, France, ²INSERM 1132, BIOSCAR, Lariboisière hospital, Paris, France, ³Inserm 1132/ Université Paris Cité, Paris, France, ⁴Radboudumc, Nijmegen, Netherlands, ⁵Université Paris cité / Inserm 1132, paris, France, ⁶Université de Nantes / Ceisam, Nantes, France, ⁷INP-ENSIACET, Toulouse, France, ⁸AP-HP, Paris, France, ⁹Lariboisière Hospital, Paris, France, ¹⁰Université Paris Cité, INSERM UMR 1132 BIOSCAR, Paris, France
Background/Purpose: Gout, due to the presence of monosodium urate crystals (MSU) and calcium pyrophosphate (CPP) crystal deposition disease are both responsible for recurrent inflammation flares.…
Abstract Number: 2023 • ACR Convergence 2024
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
Frank Fan¹, Riyong Liu¹ and Yu Wang², ¹Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), ²Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)
Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
Abstract Number: 0280 • ACR Convergence 2024
Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Mark Russell¹, Jon Massey², Edward Roddy³, Brian MacKenna⁴, Seb Bacon⁴, Ben Goldacre⁴, Colm Andrews⁴, George Hickman⁴, Amir Mehrkar², Arti Mahto⁵, Andrew Rutherford⁶, Samir Patel¹, Maryam Adas⁷, Edward Alveyn⁷, deepak Nagra¹, Katie Bechman⁷, Joanna Ledingham⁸, Joanna Hudson⁹, Sam Norton¹, Andrew Cope⁷ and James Galloway¹⁰, ¹King's College London, London, England, United Kingdom, ²University of Oxford, Oxford, England, United Kingdom, ³Keele University, Keele, England, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁶King's College Hospital NHS Foundation Trust, London, England, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁹King's College London, King's College London, United Kingdom, ¹⁰Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
Abstract Number: 2127 • ACR Convergence 2024
Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population
Isabella Silvestre Ignarro¹, Gabriela Tieme Ochikubo², Liliam Takayama³, Valeria de falco Caparbo², Camille Pinto Figueiredo², Marcos Rafael Nogueira Cavalcanti¹, Angelita Gomes De Souza¹, Isabela Judith Martins Bensenor¹, Ricardo Fuller¹ and Diogo Domiciano⁴, ¹Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Bone Metabolism Laboratory, Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, São Paulo, SP, Brazil, ³Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil
Background/Purpose: Serum uric acid (UA) has been postulated to play a role against bone loss due to antioxidant mechanisms. Some studies have shown association between…
Abstract Number: 0038 • ACR Convergence 2023
Specific Binding of Uric Acid to NDFIP1 Associates with Hyperuricemia-induced Ferroptosis
Qiunan Zhu¹, Hiroshi Arakawa², Yoshiyuki Shirasaka² and Ikumi Tamai², ¹Kanazawa University, Kanazawa, Japan, ²Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan
Background/Purpose: Hyperuricemia (HU) is reported as a risk factor for gout and associates with diverse diseases, including ulcerative colitis (UC), while its mechanism remains unclear.…
Abstract Number: 1110 • ACR Convergence 2023
Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Roy Fleischmann¹, James Cheng-Chung Wei², Zancong Shen³, sarah Morris⁴, Elizabeth Polvent⁵, Andrea Clouser-Roche⁴, Vijay Hingorani⁶, Rongzi Yan⁷, Shunqi Yan⁸, Robert Keenan⁹ and Li-Tain Yeh¹⁰, ¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ³Arthrosi Therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc, Irvine, CA, ⁸Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC, ¹⁰Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…
Abstract Number: 1111 • ACR Convergence 2023
Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis
Palapun Waitayangkoon¹, Tatchaya Kanthajan² and Thiratest Leesutipornchai³, ¹MetroWest Medical Center, Framingham, MA, ²Srinakharinwirot University, Bangkok, Thailand, ³University of Hawaii, Honolulu, HI
Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide…
Abstract Number: 0234 • ACR Convergence 2023
Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
Sara Tedeschi¹, Keigo Hayashi¹, Yuqing Zhang², Hyon K. Choi³ and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: ACR gout treatment guidelines recommend a target serum urate (SU) of < 6 mg/dL and anti-inflammatory flare prophylaxis for at least 3-6 months after…
Abstract Number: 1112 • ACR Convergence 2023
AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Zancong Shen¹, Elizabeth Polvent², sarah Morris³, Rongzi Yan⁴, Shunqi Yan⁵, Robert Keenan⁶ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Chapel Hill, NC, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: The uric acid transporter inhibitor (URAT1) is responsible for the reabsorption of filtered uric acid from the renal tubular lumen. Uricosuric agents inhibit URAT1…
Abstract Number: 0237 • ACR Convergence 2023
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
Lissa Padnick-Silver¹, Andrew Concoff², Hong-Ye Gao¹, Qianhong Fu¹, Brian LaMoreaux¹ and N. Lawrence Edwards³, ¹Horizon Therapeutics, Deerfield, IL, ²United Rheumatology, Happauge, NY, ³University of Florida College of Medicine, Gainesville, FL
Background/Purpose: Pegloticase, a recombinant pegylated uricase, rapidly reduces serum urate (SU) in patients refractory to/intolerant of oral urate-lowering therapies (ULTs).1,2 However, pegloticase is generally used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].